Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

被引:53
作者
Chande, Nilesh [1 ]
Townsend, Cassandra M. [2 ]
Parker, Claire E. [3 ]
MacDonald, John K. [2 ,3 ]
机构
[1] Victoria Hosp, London Hlth Sci Ctr, Room E6-321A,800 Commissioners Rd East, London, ON N6A 5W9, Canada
[2] Univ Western Ontario, Dept Med, London, ON, Canada
[3] Robarts Clin Trials, Cochrane IBD Grp, London, ON, Canada
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2016年 / 10期
关键词
6-Mercaptopurine [adverse effects; therapeutic use; Azathioprine [adverse effects; Crohn Disease [drug therapy; Immunosuppressive Agents [adverse effects; Induction Chemotherapy [methods; Randomized Controlled Trials as Topic; Humans; INFLAMMATORY-BOWEL-DISEASE; DOUBLE-BLIND TRIAL; EARLY COMBINED IMMUNOSUPPRESSION; INFLIXIMAB PLUS AZATHIOPRINE; TERM-FOLLOW-UP; LONG-TERM; MYCOPHENOLATE-MOFETIL; RANDOMIZED-TRIAL; CLINICAL-PHARMACOLOGY; THERAPY;
D O I
10.1002/14651858.CD000545.pub5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease have been conflicting and controversial. An updated meta-analysis was performed to assess the effectiveness of these drugs for the induction of remission in active Crohn's disease. Objectives The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction of remission in active Crohn's disease. Search methods We searched MEDLINE, EMBASE and the Cochrane Library from inception to 30 October 2015. Review articles and conference proceedings were also searched to identify additional studies. Selection criteria Randomized controlled trials (RCTs) of oral azathioprine or 6-mercaptopurine compared to placebo or active therapy involving adult patients with active Crohn's disease were selected for inclusion. Data collection and analysis Data were extracted by two independent observers based on the intention-to-treat principle. Outcomes of interest included: clinical remission, clinical improvement, fistula improvement or healing, steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. We calculated the pooled relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria. Main results Thirteen RCTs (n = 1211 patients) of azathioprine and 6-mercaptopurine therapy in adult patients were identified: nine included placebo comparators and six included active comparators. The majority of included studies were rated as low risk of bias. There was no statistically significant difference in clinical remission rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (5 studies, 380 patients; RR 1.23, 95% CI 0.97 to 1.55). There was no statistically significant difference in clinical improvement rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (107/225) of patients receiving antimetabolites achieved clinical improvement or remission compared to 36% (75/209) of placebo patients (8 studies, 434 patients; RR 1.26, 95% CI 0.98 to 1.62). There was a statistically significant difference in steroid sparing (defined as prednisone dose < 10 mg/day while maintaining remission) between azathioprine and placebo. Sixty-four per cent (47/163) of azathioprine patients were able to reduce their prednisone dose to < 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77). GRADE analyses rated the overall quality of the evidence for the outcomes clinical remission, clinical improvement and steroid sparing as moderate due to sparse data. There was no statistically significant difference in withdrawals due to adverse events or serious adverse events between antimetabolites and placebo. Ten percent of patients in the antimetabolite group withdrew due to adverse events compared to 5% of placebo patients (8 studies, 510 patients; RR 1.70, 95% CI 0.94 to 3.08). Serious adverse events were reported in 14% of patients receiving azathioprine compared to 4% of placebo patients (2 studies, 216 patients; RR 2.57, 95% CI 0.92 to 7.13). Common adverse events reported in the placebo controlled studies included: allergic reactions. leukopenia, pancreatitis and nausea. Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission. Thirty per cent (51/170) of azathioprine patients achieved steroid-free remission compared to 44% (75/169) of infliximab patients (1 study, 339 patients; RR 0.68, 95% CI 0.51 to 0.90). The combination of azathioprine and infliximab was significantly superior to infliximab alone for induction of steroid-free clinical remission. Sixty per cent (116/194) of patients in the combined azathioprine and infliximab group achieved steroid-free remission compared to 48% (91/189) of infliximab patients (2 studies, 383 patients; RR 1.23, 95% CI 1.02 to 1.47). Azathioprine or 6-mercaptopurine therapy was found to be no better at inducing steroid free clinical remission compared to methotrexate (RR 1.13, 95% CI 0.85 to 1.49) and 5-aminosalicylate or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91). There were no statistically significant differences in withdrawals due to adverse events between azathioprine or 6-mercaptopurine and methotrexate (RR 0.78, 95% CI 0.23 to 2.71); between azathioprine or 6-mercaptopurine and 5-aminosalicylate or sulfasalazine (RR 0.98, 95% CI 0.38 to 2.54); between azathioprine and infliximab (RR 1.47, 95% CI 0.96 to 2.23); or between the combination of azathioprine and infliximab and infliximab (RR 1.16, 95% CI 0.75 to 1.80). Common adverse events in the active comparator trials included nausea, abdominal pain, pyrexia and headache. Authors' conclusions Azathioprine and 6-mercaptopurine offer no advantage over placebo for induction of remission or clinical improvement in active Crohn's disease. Antimetaboilte therapy may allow patients to reduce steroid consumption. Adverse events were more common in patients receiving antimetabolites although differences with placebo were not statistically significant. Azathioprine therapy is inferior to infliximab for induction of steroid-free remission. However, the combination of azathioprine and infliximab was superior to infliximab alone for induction of steroid-free remission.
引用
收藏
页数:69
相关论文
共 50 条
  • [21] Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
    Kara Bradford
    David Q Shih
    World Journal of Gastroenterology, 2011, 17 (37) : 4166 - 4173
  • [22] Methotrexate for induction of remission in refractory Crohn's disease
    McDonald, John W. D.
    Tsoulis, David J.
    MacDonald, John K.
    Feagan, Brian G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [23] Safety of azathioprine and 6-mercaptopurine in patients with inflammatory bowel disease naive to thiopurine treatment
    Alaish, Ram
    Lundgren, David
    Suhr, Ole B.
    Werner, Marten
    Karling, Pontus
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (07) : 594 - 600
  • [24] Azathioprine/6-mercaptopurine versus 5-aminosalicylic for treatment of inflammatory bowel disease
    Chen, Xin-Lin
    She, Shi-Feng
    Li, Yu-Huang
    Zhang, Wei-Jian
    Tang, Ying-Ting
    Zhuang, Kun-Hai
    Pan, Yun-Bao
    Liu, Feng-Bin
    He, Wei-Ling
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 1927 - 1936
  • [25] Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease
    Gearry, RB
    Barclay, ML
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (08) : 1149 - 1157
  • [26] The use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel diseases
    Gutkowski, Krzysztof
    Hartleb, Marek
    PRZEGLAD GASTROENTEROLOGICZNY, 2009, 4 (05): : 225 - 230
  • [27] NK cells are biologic and biochemical targets of 6-mercaptopurine in Crohn's disease patients
    Yusung, Susy
    McGovern, Dermot
    Lin, Lin
    Hommes, Daniel
    Lagishetty, Venu
    Braun, Jonathan
    CLINICAL IMMUNOLOGY, 2017, 175 : 82 - 90
  • [28] Effects of azathioprine, 6-mercaptopurine, and 6-thioguanine on canine primary hepatocytes
    LaDuke, Kathleen E.
    Ehling, Sarah
    Cullen, John M.
    Baeumer, Wolfgang
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2015, 76 (07) : 649 - 655
  • [29] Azathioprine/6-mercaptopurine toxicity: The role of the TPMT gene
    Katsanos, K. H.
    Tsianos, E. V.
    ANNALS OF GASTROENTEROLOGY, 2007, 20 (04): : 251 - 264
  • [30] Use of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease Previously Intolerant of Azathioprine
    David G. Bowen
    Warwick S. Selby
    Digestive Diseases and Sciences, 2000, 45 : 1810 - 1813